Hyperlipidemia in coronary heart disease: A biochemical genetic approach

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A population genetic study was carried out in order to identify and classify the clinical forms of familial hyperlipidemia that predispose to coronary heart disease. Five hundred consecutive survivors of myocardial infarction in Seattle were ascertained, and extensive family studies were then performed. Three simply inherited forms of hyperlipidemia were identified - familial hypercholesterolemia, familial hypertriglyceridemia, and familial combined hyerlipidemia. Together, these three disorders were present in 20 per cent of the survivors under 60 years of age. To us, the most exciting finding was that each of these disorders appeared to be transmitted by a single gene mechanism, indicating that each disorder may be caused by a single biochemical defect that should be identifiable at the molecular level. On the negative side, we were disappointed to find that there was no consistent relationship between the plasma lipoprotein pattern in a given patient and his genetic disorder. None of the lipoprotein types proved specific for any of the three familial disorders; and conversely, none of the familial disorders were specified by a single lipoprotein type. From these studies, we concluded that lipoprotein typing would be of limited use in the search for the basic defects. At this piont, it seemed clear that a new sytem was needed that would allow delineation of underlying defects in lipid or lipoprotein metabolism in these genetically determined disorders. Two years ago in Dallas, we began a series of studies to search for these molecular lesions. Familial hypercholesterolemia was the disorder that we first chose to study. Of all the hereditary forms of hyperlipidemia, this disorder is the outstanding example of a single-gene mutation producing both elevated cholesterol and atherosclerosis. Moreover, familial hypercholesterolemia is one of the most common genetic diseases affecting man. About 1 out of 500 people in the general population is a heterozygote for the dominant familial hypercholesterolemia gene, making this disorder more common than either cystic fibrosis or sickle cell anemia.

Original languageEnglish (US)
Pages (from-to)174-181
Number of pages8
JournalJournal of Laboratory and Clinical Medicine
Volume108
Issue number3
StatePublished - 1986

Fingerprint

Hyperlipidemias
Hyperlipoproteinemia Type II
Lipoproteins
Coronary Disease
Molecular Biology
Inborn Genetic Diseases
Genes
Defects
Survivors
Hyperlipoproteinemia Type IV
Population Genetics
Sickle Cell Anemia
Heterozygote
Hypercholesterolemia
Metabolism
Cystic Fibrosis
Atherosclerosis
Myocardial Infarction
Cholesterol
Lipids

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

@article{b3cc1e30c40c49b9b760632e4f05e304,
title = "Hyperlipidemia in coronary heart disease: A biochemical genetic approach",
abstract = "A population genetic study was carried out in order to identify and classify the clinical forms of familial hyperlipidemia that predispose to coronary heart disease. Five hundred consecutive survivors of myocardial infarction in Seattle were ascertained, and extensive family studies were then performed. Three simply inherited forms of hyperlipidemia were identified - familial hypercholesterolemia, familial hypertriglyceridemia, and familial combined hyerlipidemia. Together, these three disorders were present in 20 per cent of the survivors under 60 years of age. To us, the most exciting finding was that each of these disorders appeared to be transmitted by a single gene mechanism, indicating that each disorder may be caused by a single biochemical defect that should be identifiable at the molecular level. On the negative side, we were disappointed to find that there was no consistent relationship between the plasma lipoprotein pattern in a given patient and his genetic disorder. None of the lipoprotein types proved specific for any of the three familial disorders; and conversely, none of the familial disorders were specified by a single lipoprotein type. From these studies, we concluded that lipoprotein typing would be of limited use in the search for the basic defects. At this piont, it seemed clear that a new sytem was needed that would allow delineation of underlying defects in lipid or lipoprotein metabolism in these genetically determined disorders. Two years ago in Dallas, we began a series of studies to search for these molecular lesions. Familial hypercholesterolemia was the disorder that we first chose to study. Of all the hereditary forms of hyperlipidemia, this disorder is the outstanding example of a single-gene mutation producing both elevated cholesterol and atherosclerosis. Moreover, familial hypercholesterolemia is one of the most common genetic diseases affecting man. About 1 out of 500 people in the general population is a heterozygote for the dominant familial hypercholesterolemia gene, making this disorder more common than either cystic fibrosis or sickle cell anemia.",
author = "Goldstein, {J. L.} and Brown, {M. S.}",
year = "1986",
language = "English (US)",
volume = "108",
pages = "174--181",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Hyperlipidemia in coronary heart disease

T2 - A biochemical genetic approach

AU - Goldstein, J. L.

AU - Brown, M. S.

PY - 1986

Y1 - 1986

N2 - A population genetic study was carried out in order to identify and classify the clinical forms of familial hyperlipidemia that predispose to coronary heart disease. Five hundred consecutive survivors of myocardial infarction in Seattle were ascertained, and extensive family studies were then performed. Three simply inherited forms of hyperlipidemia were identified - familial hypercholesterolemia, familial hypertriglyceridemia, and familial combined hyerlipidemia. Together, these three disorders were present in 20 per cent of the survivors under 60 years of age. To us, the most exciting finding was that each of these disorders appeared to be transmitted by a single gene mechanism, indicating that each disorder may be caused by a single biochemical defect that should be identifiable at the molecular level. On the negative side, we were disappointed to find that there was no consistent relationship between the plasma lipoprotein pattern in a given patient and his genetic disorder. None of the lipoprotein types proved specific for any of the three familial disorders; and conversely, none of the familial disorders were specified by a single lipoprotein type. From these studies, we concluded that lipoprotein typing would be of limited use in the search for the basic defects. At this piont, it seemed clear that a new sytem was needed that would allow delineation of underlying defects in lipid or lipoprotein metabolism in these genetically determined disorders. Two years ago in Dallas, we began a series of studies to search for these molecular lesions. Familial hypercholesterolemia was the disorder that we first chose to study. Of all the hereditary forms of hyperlipidemia, this disorder is the outstanding example of a single-gene mutation producing both elevated cholesterol and atherosclerosis. Moreover, familial hypercholesterolemia is one of the most common genetic diseases affecting man. About 1 out of 500 people in the general population is a heterozygote for the dominant familial hypercholesterolemia gene, making this disorder more common than either cystic fibrosis or sickle cell anemia.

AB - A population genetic study was carried out in order to identify and classify the clinical forms of familial hyperlipidemia that predispose to coronary heart disease. Five hundred consecutive survivors of myocardial infarction in Seattle were ascertained, and extensive family studies were then performed. Three simply inherited forms of hyperlipidemia were identified - familial hypercholesterolemia, familial hypertriglyceridemia, and familial combined hyerlipidemia. Together, these three disorders were present in 20 per cent of the survivors under 60 years of age. To us, the most exciting finding was that each of these disorders appeared to be transmitted by a single gene mechanism, indicating that each disorder may be caused by a single biochemical defect that should be identifiable at the molecular level. On the negative side, we were disappointed to find that there was no consistent relationship between the plasma lipoprotein pattern in a given patient and his genetic disorder. None of the lipoprotein types proved specific for any of the three familial disorders; and conversely, none of the familial disorders were specified by a single lipoprotein type. From these studies, we concluded that lipoprotein typing would be of limited use in the search for the basic defects. At this piont, it seemed clear that a new sytem was needed that would allow delineation of underlying defects in lipid or lipoprotein metabolism in these genetically determined disorders. Two years ago in Dallas, we began a series of studies to search for these molecular lesions. Familial hypercholesterolemia was the disorder that we first chose to study. Of all the hereditary forms of hyperlipidemia, this disorder is the outstanding example of a single-gene mutation producing both elevated cholesterol and atherosclerosis. Moreover, familial hypercholesterolemia is one of the most common genetic diseases affecting man. About 1 out of 500 people in the general population is a heterozygote for the dominant familial hypercholesterolemia gene, making this disorder more common than either cystic fibrosis or sickle cell anemia.

UR - http://www.scopus.com/inward/record.url?scp=0022922233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022922233&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0022922233

VL - 108

SP - 174

EP - 181

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 3

ER -